Lopinavir/ritonavir (LPV/r) pellets are a new formulation of a pediatric HIV medicine. The LPV/r Pellet Toolkit provides information on how to implement rollout of LPV/r pellets into the national health care system in the Rollout Planning and Management section.
Evidence regarding potential adverse neuropsychiatric effects of efavirenz is conflicting, and data from sub-Saharan Africa, where 70% of persons living with HIV (PLHIV) reside and efavirenz is used as first-line therapy, are limited. The objective of this study was to estimate associations betwe
Treatment with the antiretroviral drug efavirenz did not increase the risk of depressive symptoms or suicidal thoughts in adults living with HIV in Uganda when compared to nevirapine-based treatment, a prospective cohort study published in Annals of Internal Medicine reports.